Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yanping Hu

Showing results (191-200 of 200) with videos related to

Pageof 20
Sort By:
You have reached the last page of results.This site can display upto 200 results.
IMA Fungus|March 7, 2025
IMA GENOME - F20 A draft genome assembly of <i>Agroatheliarolfsii</i>, <i>Ceratobasidiumpapillatum</i>, <i>Pyrenopezizabrassicae</i>, <i>Neopestalotiopsismacadamiae</i>, <i>Sphaerellopsisfilum</i> and genomic resources for <i>Colletotrichumspaethianum</i> and <i>Colletotrichumfructicola</i>Davide D'Angelo, Roberto Sorrentino, Tiphany Nkomo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 6, 2022
Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b StudyYuankai Shi, Baolan Li, Lin Wu, et al.
The Lancet. Respiratory Medicine|December 15, 2023
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trialMengzhao Wang, Yun Fan, Meili Sun, et al.
Med (New York, N.Y.)|October 10, 2024
First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trialQing Zhou, Yan Yu, Ligang Xing, et al.
Blood|April 21, 2024
A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndromeRaffaele Badolato, Laia Alsina, Antoine Azar, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 21, 2021
Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational TrialShun Lu, Qiming Wang, Guojun Zhang, et al.
Lung Cancer (Amsterdam, Netherlands)|June 28, 2020
A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer - The FALUCA studyShun Lu, Gongyan Chen, Yuping Sun, et al.
Nature Medicine|January 6, 2025
Glecirasib in KRAS<sup>G12C</sup>-mutated nonsmall-cell lung cancer: a phase 2b trialYuankai Shi, Jian Fang, Ligang Xing, et al.
Cancer Communications (London, England)|July 17, 2024
Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR-mutated, advanced non-small cell lung cancer: data from a randomized phase III trial (AENEAS)Shun Lu, Xiaorong Dong, Hong Jian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 17, 2022
AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With <i>EGFR</i> Exon 19 Deletion or L858R MutationsShun Lu, Xiaorong Dong, Hong Jian, et al.
Pageof 20

Showing results (191-200 of 200) with videos related to

Sort By:
Pageof 20
You have reached the last page of results.This site can display upto 200 results.
IMA Fungus|March 7, 2025
IMA GENOME - F20 A draft genome assembly of <i>Agroatheliarolfsii</i>, <i>Ceratobasidiumpapillatum</i>, <i>Pyrenopezizabrassicae</i>, <i>Neopestalotiopsismacadamiae</i>, <i>Sphaerellopsisfilum</i> and genomic resources for <i>Colletotrichumspaethianum</i> and <i>Colletotrichumfructicola</i>Davide D'Angelo, Roberto Sorrentino, Tiphany Nkomo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 6, 2022
Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b StudyYuankai Shi, Baolan Li, Lin Wu, et al.
The Lancet. Respiratory Medicine|December 15, 2023
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trialMengzhao Wang, Yun Fan, Meili Sun, et al.
Med (New York, N.Y.)|October 10, 2024
First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trialQing Zhou, Yan Yu, Ligang Xing, et al.
Blood|April 21, 2024
A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndromeRaffaele Badolato, Laia Alsina, Antoine Azar, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 21, 2021
Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational TrialShun Lu, Qiming Wang, Guojun Zhang, et al.
Lung Cancer (Amsterdam, Netherlands)|June 28, 2020
A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer - The FALUCA studyShun Lu, Gongyan Chen, Yuping Sun, et al.
Nature Medicine|January 6, 2025
Glecirasib in KRAS<sup>G12C</sup>-mutated nonsmall-cell lung cancer: a phase 2b trialYuankai Shi, Jian Fang, Ligang Xing, et al.
Cancer Communications (London, England)|July 17, 2024
Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR-mutated, advanced non-small cell lung cancer: data from a randomized phase III trial (AENEAS)Shun Lu, Xiaorong Dong, Hong Jian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 17, 2022
AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With <i>EGFR</i> Exon 19 Deletion or L858R MutationsShun Lu, Xiaorong Dong, Hong Jian, et al.
Pageof 20